 |
PDBsum entry 4brx
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Synthesis of novel diarylamino-1,3,5-Triazine derivatives as fak inhibitors with anti-Angiogenic activity.
|
 |
|
Authors
|
 |
P.Dao,
R.Jarray,
J.Le coq,
D.Lietha,
A.Loukaci,
Y.Lepelletier,
R.Hadj-Slimane,
C.Garbay,
F.Raynaud,
H.Chen.
|
 |
|
Ref.
|
 |
Bioorg Med Chem Lett, 2013,
23,
4552-4556.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
We report herein the synthesis of novel diarylamino-1,3,5-triazine derivatives
as FAK (focal adhesion kinase) inhibitors and the evaluation of their
anti-angiogenic activity on HUVEC cells. Generally, the effects of these
compounds on endothelial cells could be correlated with their kinase inhibitory
activity. The most efficient compounds displayed inhibition of viability against
HUVEC cells in the micromolar range, as observed with TAE-226, which was
designed by Novartis Pharma AG. X-ray crystallographic analysis of the
co-crystal structure for compound 34 revealed that the mode of interaction with
the FAK kinase domain is highly similar to that observed in the complex of
TAE-226.
|
 |
|
|
|
|
 |